To assess the utility of this strategy for clinical translation, we treated B-cell lymphoma xenograft mice with 28z and 28z/IL-7 CAR-T cells were persistent in vivo, rapidly diminished the tumor cell burden, and achieved superior survival , indicating the mechanism underlying the functional and proliferative advantage observed in vitro is mainly driven by IL-7. Here, IL7 is linked to B-cell non-Hodgkin lymphoma.